Written by Jane Aubrey
Oncolytics Biotech has secured FDA written feedback that could make the development path for pelareorep in metastatic colorectal cancer more efficient. The company says the agency’s responses support a potential transition from the ongoing randomized Part A of REO 033 into a pivotal Part B expansion, with objective response rate and duration of response potentially supporting accelerated approval and progression-free survival intended to support full approval.
That is valuable regulatory progress, but it is not clinical proof. The entire strategy remains contingent on positive data from the current study. Investors, clinicians and patients should distinguish between an agency agreeing that a proposed pathway can be reasonable and an agency concluding that a therapy has demonstrated sufficient benefit for approval.
In its August 18 announcement, Oncolytics said it received written FDA feedback on the potential pivotal expansion of REO 033. The study is evaluating intravenously delivered pelareorep in combination with FOLFIRI chemotherapy and bevacizumab against FOLFIRI and bevacizumab alone in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
This is a difficult treatment setting. Microsatellite-stable colorectal tumors generally do not respond as well to immunotherapy as microsatellite-instability-high disease, and RAS mutations narrow therapeutic options. A regimen that improves response, progression-free survival or ultimately overall survival without creating an unacceptable safety burden would address a substantial unmet need. But metastatic colorectal cancer has repeatedly shown that biological rationale alone does not reliably translate into meaningful patient benefit.
Pelareorep is an investigational double-stranded RNA immunotherapy designed to selectively replicate in tumor cells while activating innate and adaptive anti-tumor responses. The company says it may help convert immunologically “cold” tumors into more inflamed tumors, including through cytokine effects and expansion of tumor-infiltrating lymphocytes. It has been administered to more than 1,200 patients across clinical studies, and it has FDA Fast Track designation in the relevant colorectal setting.
The regulatory design is the immediate news. Oncolytics asked whether its existing randomized Part A could support expansion into a pivotal Part B and whether Part B could potentially support accelerated approval based on response measures, with progression-free survival serving as the confirmatory basis for full approval. According to the company, FDA written feedback provided meaningful alignment and suggested that the company hold an End-of-Phase meeting to finalize key registration-program elements.
The company therefore plans to forego a previously scheduled Type D meeting and instead pursue the more consequential End-of-Phase meeting as the program advances. It intends to start Part B preparations once supportive interim data from Part A are available, with the goal of reducing time between the data readout and a potential pivotal launch.
The sequence is crucial. Part A is a randomized controlled study with 60 participants. It is designed to generate the clinical evidence needed to decide whether a pivotal expansion is justified. Oncolytics is not claiming that Part B has been approved, that accelerated approval is assured or that pelareorep’s benefit has been established in REO 033. The FDA feedback sets out a possible road; the study must still produce results strong enough to travel it.
Previous pelareorep studies, including REO 022, have generated what the company describes as encouraging signals in response rate, response duration, progression-free survival and overall survival when combined with standard therapy. Those results provide a rationale for the present randomized trial, but they do not replace controlled evidence in the target population. Small or non-randomized oncology studies can overstate apparent benefit because patient selection, prior treatment, tumor biology and chance all influence outcomes.
The eventual evidentiary standard will be demanding. Objective response rate must be durable, not merely transient imaging shrinkage. Progression-free survival will need to show a clinically relevant advantage, and overall survival will remain an important contextual measure even if not the immediate accelerated-approval endpoint. Safety is equally important because FOLFIRI and bevacizumab already carry substantial toxicity, and any immunotherapy addition must deliver enough benefit to justify incremental risk.
Oncolytics’ announcement is best seen as a reduction in regulatory uncertainty rather than a reduction in scientific uncertainty. The FDA has indicated that a coherent pivotal strategy may be available. That can help the company allocate capital and plan operations. The next true value inflection is initial randomized Part A data. Only then will the field learn whether pelareorep can convert a credible mechanistic theory into a registrational-quality treatment effect for patients with RAS-mutant, microsatellite-stable metastatic colorectal cancer.
